A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Condition: Colitis, Ulcerative
MeSH terms: Colitis; Colitis, Ulcerative; Ulcer
Intervention: Etrolizumab; Placebo
Intervention description: Participants will receive 105 mg etrolizumab SC injection Q4W.; Participants will receive placebo (matched to etrolizumab) SC injection Q4W.
Intervention MeSH terms: Etrolizumab
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 359.0
Sex: All
Minimum age: 18 Years
Maximum age: 80 Years
Healthy volunteers: No

Summary:

      This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter
      study will investigate the efficacy and safety of etrolizumab in maintenance of remission in
      participants with moderately to severely active UC who are naive to TNF inhibitors and
      refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of ulcerative colitis (UC) established at least 3 months prior to Day 1 by
             clinical and endoscopic evidence

          -  Moderately to severely active UC as determined by an MCS of 6-12 with an endoscopic
             subscore greater than or equal to (≥)2 as determined by the central reading procedure
             (endoscopy to be performed 4-16 days prior to Day 1), a rectal bleeding subscore ≥1,
             and a stool frequency subscore ≥1 during the screening period (prior to Day 1)

          -  Evidence of UC extending a minimum of 20 centimeters (cm) from the anal verge as
             determined by baseline endoscopy (flexible sigmoidoscopy or colonoscopy) performed
             during screening, 4-16 days prior to Day 1

          -  Naive to treatment with any anti-TNF therapy

          -  Participants must have had an inadequate response, loss of response, or intolerance to
             prior corticosteroid and/or immunosuppressant treatment

          -  Background regimen for UC may include oral 5-aminosalicylate (5-ASA), oral
             corticosteroids, budesonide, probiotics, azathioprine (AZA), 6-mercaptopurine (6-MP),
             or methotrexate (MTX) if doses have been stable during the screening period

          -  Use of highly effective contraception

          -  Must have received a colonoscopy within the past year or be willing to undergo a
             colonoscopy in lieu of a flexible sigmoidoscopy at screening

        Exclusion Criteria:

          -  A history of or current conditions and diseases affecting the digestive tract, such as
             indeterminate colitis, suspicion of ischemic colitis, radiation colitis, or
             microscopic colitis, Crohn's disease, fistulas or abdominal abscesses, colonic mucosal
             dysplasia, intestinal obstruction, toxic megacolon, or unremoved adenomatous colonic
             polyps

          -  Prior or planned surgery for UC

          -  Past or present ileostomy or colostomy

          -  Any prior treatment with etrolizumab or other anti-integrin agents (including
             natalizumab, vedolizumab, and efalizumab) as stated in the protocol

          -  Any prior treatment with anti-adhesion molecules (such as mucosal addressin cell
             adhesion molecule [MAdCAM-1])

          -  Any prior treatment with rituximab

          -  Any treatment with tofacitinib during screening

          -  Cogenital or acquired immune deficiency, chronic hepatitis B or C infection, human
             immunodeficiency virus (HIV) positive, or history of tuberculosis (active or latent)

          -  Evidence of or treatment for Clostridium difficile within 60 days prior to Day 1 or
             other intestinal pathogens within 30 days prior to Day 1

          -  History of recurrent opportunistic infections and/or severe disseminated viral
             infections

          -  History of organ transplant

          -  Any major episode of infection requiring treatment with intravenous (IV) antibiotics
             within 8 weeks prior to screening or oral antibiotics within 4 weeks prior to
             screening

          -  Received a live attenuated vaccine within 4 weeks prior to Day 1